Coherus reports PK data for Humira biosimilar

Coherus BioSciences Inc. (Redwood City, Calif.) said CHS-1420, its biosimilar of Humira adalimumab, met the primary endpoint of pharmacokinetic similarity to Humira. PK endpoints measured maximum serum concentration, area under the time-concentration curve from first to last time point measured and area under the time-concentration curve from first time point extrapolated to infinity. The company said it will advance to the next phase of development but did not disclose further details. ...